Sclerosis: Types, Causes, and Clinical Significance

Sclerosis refers to the pathological hardening or thickening of tissue due to excessive fibrous connective tissue deposition (fibrosis) or abnormal mineralization. It results from chronic inflammation, injury, metabolic dysfunction, autoimmune processes, or aging, leading to loss of elasticity and impaired organ function.

Major Types and Conditions

Vascular

• Atherosclerosis: Lipid-rich plaque buildup in arterial intima → stenosis, ischemia, MI, stroke.
• Arteriolosclerosis: Hyaline (hypertension/diabetes) or hyperplastic (malignant HTN) thickening of arterioles.
• Mönckeberg's sclerosis: Medial calcific degeneration of muscular arteries; often asymptomatic.

Neurological

• Multiple sclerosis (MS): Autoimmune demyelination of CNS → plaques/scars → motor, sensory, cognitive deficits.
• Amyotrophic lateral sclerosis (ALS): Degeneration of upper and lower motor neurons → progressive weakness, atrophy.
• Lateral sclerosis (primary lateral sclerosis): Upper motor neuron only; slower progression.

Organ-Specific

• Liver cirrhosis: Fibrotic nodules replace hepatic architecture → portal hypertension, liver failure.
• Nephrosclerosis: Renal arteriolar thickening → ischemic glomerular loss → CKD.
• Systemic sclerosis (scleroderma): Autoimmune fibrosis of skin, vasculature, GI tract, lungs, kidneys, heart.
• Idiopathic pulmonary fibrosis (IPF): Progressive lung scarring → restrictive physiology, hypoxia.
• Cardiac sclerosis: Post-infarct or interstitial fibrosis → diastolic dysfunction, arrhythmia substrate.

Other

• Tuberous sclerosis: Genetic (TSC1/2) → hamartomas in brain, kidneys, heart, skin, lungs.
• Senile sclerosis: Age-related tissue stiffening (lens, vessels, valves).

Pathophysiology

Common pathways: TGF-β signaling → fibroblast activation → collagen I/III deposition → cross-linking → tissue stiffening. Inflammatory cytokines (IL-6, TNF-α), oxidative stress, and mechanical stress perpetuate the cycle.

Diagnosis and Management

• Imaging: ultrasound elastography, MRI, CT, fibroscan (liver).
• Biomarkers: specific to etiology (e.g., autoantibodies, lipids, genetic testing).
• Treatment targets underlying cause: immunosuppression (autoimmune), lipid/BP control (vascular), antifibrotics (IPF), disease-modifying therapies (MS).
• Symptom management and organ support as needed.

Early detection and etiology-specific intervention are crucial to slow progression and preserve function.